Developer docs
API playgroundTry for free, no card

Search company profiles

CymaBay Therapeutics

Full company profile

uuid00042r6

Namestring
CymaBay Therapeutics
Legal namestring
CymaBay Therapeutics, Inc.
Websiteurl
cymabay.com
Company typeenum
Private
Founded yearint
1991
Descriptiontext

CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company focused on developing proprietary small-molecule therapies for liver diseases. Its lead and primary asset was seladelpar, a first-in-class PPAR-delta agonist evaluated for Primary Biliary Cholangitis (PBC) — a rare autoimmune disease affecting the bile ducts — and for Metabolic dysfunction-Associated Steatohepatitis (MASH). Seladelpar received FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, becoming the first approved treatment for PBC patients in the European Economic Area. The company's underlying technology centered on selective PPAR-delta modulation, a differentiated mechanism of action within the PPAR receptor family that the company developed through Phase I–III clinical development.

During its independent operation, CymaBay functioned as a pre-commercial R&D entity with no product revenue. Development was funded through a mix of public equity offerings on NASDAQ (CBAY) and non-dilutive debt financing — including approximately $258.7 million raised in September 2023, $85 million planned in January 2023, $75 million in November 2021, and a $100 million non-dilutive facility from Abingworth in August 2021. The business model relied on advancing a single high-conviction asset through regulatory milestones rather than building a commercial sales force; revenue mechanics under independent ownership were limited to milestone payments and capital markets activity.

In 2024, Gilead Sciences acquired CymaBay for approximately $4.3–4.4 billion, integrating seladelpar into Gilead's liver disease franchise under the brand LivDelzi. Following the acquisition, CymaBay operates as a wholly-owned subsidiary of Gilead Sciences and no longer functions as an independent commercial entity.

Short descriptiontext

CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company developing seladelpar, a first-in-class PPAR-delta agonist for Primary Biliary Cholangitis and MASH, acquired by Gilead Sciences in 2024 for approximately $4.3–4.4 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
liver disease therapeutics, rare disease drugs, primary biliary cholangitis treatment, PPAR-delta agonist, specialty biopharmaceuticals
Industry4 codes
1Gastroenterology & Hepatology Pharmaceuticals
CodeHLAIAAAIPrimaryYes
2Hepatology & Liver Disease
CodeHLAKAEABPrimaryNo
3Immunology & Inflammation Pharmaceuticals
CodeHLAIAAADPrimaryNo
4Regulatory Strategy & IND/NDA/BLA Submissions Support
CodeHLAIALAHPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CymaBay Therapeutics develops and commercializes proprietary biopharmaceutical therapies targeting liver diseases, with seladelpar as its lead asset. Seladelpar is a first-in-class PPAR-delta agonist for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease, with additional development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The drug received FDA accelerated approval in August 2024 and EU conditional marketing authorization in February 2025, and is now sold under the brand LivDelzi by Gilead Sciences following its acquisition of CymaBay.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FDA accelerated approval received August 2024
+1 more record
Product overview1 text field

CymaBay Therapeutics was a biotech company focused on developing innovative therapies for liver diseases. The company's primary product was seladelpar, a drug candidate targeting Primary Biliary Cholangitis (PBC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Following Gilead Sciences' acquisition of CymaBay in 2024 for approximately $4.3 billion, seladelpar was commercialized under the brand LivDelzi. The company conducted clinical trials across Phase I through Phase III stages and secured non-dilutive financing from Abingworth to support Phase 3 trials.

Product and service1 record
1Seladelpar (LivDelzi)
CategorySpecialty Biopharmaceuticals / Liver Disease Therapeutics
Description

Seladelpar is a first-in-class PPAR-delta agonist developed by CymaBay Therapeutics for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease. It also targets Metabolic dysfunction-Associated Steatohepatitis (MASH). Following FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, the drug is commercialized by Gilead Sciences under the brand LivDelzi.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CymaBay Therapeutics

Specialty Biopharmaceuticalscymabay.com

CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company developing seladelpar, a first-in-class PPAR-delta agonist for Primary Biliary Cholangitis and MASH, acquired by Gilead Sciences in 2024 for approximately $4.3–4.4 billion.

What CymaBay Therapeutics does

CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company focused on developing proprietary small-molecule therapies for liver diseases. Its lead and primary asset was seladelpar, a first-in-class PPAR-delta agonist evaluated for Primary Biliary Cholangitis (PBC) — a rare autoimmune disease affecting the bile ducts — and for Metabolic dysfunction-Associated Steatohepatitis (MASH). Seladelpar received FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, becoming the first approved treatment for PBC patients in the European Economic Area. The company's underlying technology centered on selective PPAR-delta modulation, a differentiated mechanism of action within the PPAR receptor family that the company developed through Phase I–III clinical development.

During its independent operation, CymaBay functioned as a pre-commercial R&D entity with no product revenue. Development was funded through a mix of public equity offerings on NASDAQ (CBAY) and non-dilutive debt financing — including approximately $258.7 million raised in September 2023, $85 million planned in January 2023, $75 million in November 2021, and a $100 million non-dilutive facility from Abingworth in August 2021. The business model relied on advancing a single high-conviction asset through regulatory milestones rather than building a commercial sales force; revenue mechanics under independent ownership were limited to milestone payments and capital markets activity.

In 2024, Gilead Sciences acquired CymaBay for approximately $4.3–4.4 billion, integrating seladelpar into Gilead's liver disease franchise under the brand LivDelzi. Following the acquisition, CymaBay operates as a wholly-owned subsidiary of Gilead Sciences and no longer functions as an independent commercial entity.

CymaBay Therapeutics firmographics

Firmographics
Name
CymaBay Therapeutics
Legal name
CymaBay Therapeutics, Inc.
Website
https://cymabay.com
Company type
Private
Founded year
1991
Operating status
Acquired
Headcount range
51–100 employees
Short description
CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company developing seladelpar, a first-in-class PPAR-delta agonist for Primary Biliary Cholangitis and MASH, acquired by Gilead Sciences in 2024 for approximately $4.3–4.4 billion.
Ownership category
akta.pro rank

CymaBay Therapeutics industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
akta.pro secondary industries
Hepatology & Liver Disease (HLAKAEAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

  • Liver disease therapeutics
  • Rare disease drugs
  • Primary biliary cholangitis treatment
  • PPAR-delta agonist
  • Specialty biopharmaceuticals

Where CymaBay Therapeutics is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Markets served

CymaBay Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

CymaBay Therapeutics product offering

Product offering

Core offering

CymaBay Therapeutics develops and commercializes proprietary biopharmaceutical therapies targeting liver diseases, with seladelpar as its lead asset. Seladelpar is a first-in-class PPAR-delta agonist for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease, with additional development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The drug received FDA accelerated approval in August 2024 and EU conditional marketing authorization in February 2025, and is now sold under the brand LivDelzi by Gilead Sciences following its acquisition of CymaBay.

Product overview

CymaBay Therapeutics was a biotech company focused on developing innovative therapies for liver diseases. The company's primary product was seladelpar, a drug candidate targeting Primary Biliary Cholangitis (PBC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Following Gilead Sciences' acquisition of CymaBay in 2024 for approximately $4.3 billion, seladelpar was commercialized under the brand LivDelzi. The company conducted clinical trials across Phase I through Phase III stages and secured non-dilutive financing from Abingworth to support Phase 3 trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seladelpar (LivDelzi) Seladelpar is a first-in-class PPAR-delta agonist developed by CymaBay Therapeutics for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease. It also targets Metabolic dysfunction-Associated Steatohepatitis (MASH). Following FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, the drug is commercialized by Gilead Sciences under the brand LivDelzi.

Quantifiable outcome

  • FDA accelerated approval received August 2024
  • +1 more outcomes

Companies that use CymaBay Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

CymaBay Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

CymaBay Therapeutics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

CymaBay Therapeutics competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

CymaBay Therapeutics social profiles

Digital presence

CymaBay Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CymaBay Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

CymaBay Therapeutics funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CymaBay Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CymaBay Therapeutics

What does CymaBay Therapeutics do?

CymaBay Therapeutics develops and commercializes proprietary biopharmaceutical therapies targeting liver diseases, with seladelpar as its lead asset. Seladelpar is a first-in-class PPAR-delta agonist for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease, with additional development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The drug received FDA accelerated approval in August 2024 and EU conditional marketing authorization in February 2025, and is now sold under the brand LivDelzi by Gilead Sciences following its acquisition of CymaBay.

Is CymaBay Therapeutics a public or private company?

CymaBay Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was CymaBay Therapeutics founded?

CymaBay Therapeutics was founded in 1991. It employs 51 to 100 people.

Where is CymaBay Therapeutics based?

CymaBay Therapeutics is headquartered in Hayward, United States, in the North America region.

Does CymaBay Therapeutics have an API?

No public API is recorded for CymaBay Therapeutics.

What industry is CymaBay Therapeutics in?

CymaBay Therapeutics's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAKAEAB, Hepatology & Liver Disease. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMetabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market (2026-2033) | NASH Drug Development, Liver Fibrosis Drugs, Drug Approvals, & Global Market InsightsDataM Intelligence published a market research report on the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, valued at US$ 1.67 billion in 2023 and projected to reach US$ 7.64 billion by 2031, growing at a CAGR of 21.8% during 2024-2031. The report identifies key growth drivers including rising prevalence of metabolic disorders, FDA approvals such as Madrigal Pharmaceuticals' Rezdiffra, and advancements in GLP-1 and combination therapies. Notable M&A activity in 2026 includes Novo Nordisk's minority stake in Echosens, Gilead Sciences' acquisition of CymaBay Therapeutics, and AstraZeneca's licensing deal with Ionis Pharmaceuticals for a preclinical MASH candidate.openPR.comPrimary Biliary Cholangitis Pipeline Set for Major Breakthroughs by 2026 with 25+ Therapies and Strong Clinical Momentum from GlaxoSmithKline, Novartis, and CymaBay Therapeutics | DelveInsightDelveInsight's Primary Biliary Cholangitis Pipeline Insight 2026 report identifies 20+ companies developing 25+ pipeline therapies for PBC, a rare autoimmune liver disease. In March 2026, GSK finalized a commercialization deal with Alfasigma for linerixibat, including a $300 million upfront payment, following FDA NDA acceptance in June 2025 with a PDUFA goal date of March 24, 2026. In February 2025, the European Commission granted conditional marketing authorization for Gilead Sciences' seladelpar, marking the first approved treatment option for PBC patients in the EEA.openPR.comPrimary Biliary Cholangitis Market Outlook 2034: Growth Momentum Strengthens with Emerging Pipeline Innovations | DelveInsightDelveInsight's market report on Primary Biliary Cholangitis valued the global market at USD 1.15 billion in 2023, projecting notable growth through 2034 driven by pipeline innovations and increasing disease awareness. Key regulatory milestones include FDA accelerated approval of seladelpar (CymaBay Therapeutics) in August 2024, conditional EU approval of elafibranor by Ipsen, and a positive CHMP opinion for seladelpar from Gilead Sciences, alongside a $300 million deal in which GSK granted Alfasigma commercialization rights for linerixibat. In September 2025, Intercept Pharmaceuticals withdrew Ocaliva from the US market due to FDA concerns over serious liver injury risks, highlighting ongoing safety challenges in the PBC treatment landscape.Astute AnalyticaCell and Gene Therapy Market Size, Share & Growth [2035]The global cell and gene therapy market was valued at $36.5 billion in 2024 and is projected to reach $183.1 billion by 2035, growing at a CAGR of 17.5% during the forecast period. Gene therapy leads by revenue contribution at 54%, driven by high-priced one-time treatments like Zolgensma ($2.1 million) and Elevidys ($3.2 million), with oncology remaining the dominant therapeutic area. The sector attracted $15.2 billion in funding in 2024, supported by over 3,000 developers, more than 2,000 clinical trials globally, and major acquisitions including Gilead's $4.3 billion purchase of CymaBay, AstraZeneca's $1.05 billion acquisition of Amolyt Pharma, and Bristol-Myers Squibb's $14 billion acquisition of Karuna Therapeutics.FortreaBiotech Industry Trends 2025: Key Developments and InsightsAs of April 2025, emerging pharmaceutical companies with R&D expenditure under US$300 million are sponsoring 8,684 investigative drugs under active development, with 46% in preclinical stage and 57% sponsored by companies with no approved therapies in their portfolio. The article notes that only 5% of innovator drugs originate from the top 50 R&D spenders, highlighting how smaller biotech firms drive pharmaceutical innovation despite facing significant financial and scientific risks that often lead to acquisition by larger pharma companies. Notable 2024 acquisitions cited include Gilead Sciences' purchase of CymaBay Therapeutics and Bristol Myers Squibb's acquisition of Karuna Therapeutics, illustrating how large pharma increasingly relies on acquiring biotech assets rather than building molecules internally.AbingworthClinical Co-DevelopmentAbingworth Clinical Co-Development (ACCD) offers financing solutions to companies for drug development, taking on financial risks and ensuring payments are only due upon drug approval. The funding is designed to foster expansion and lifecycle management of development programs, with recent notable collaborations including Teva's Phase 3 clinical trials for severe asthma relief and Gilead Sciences' acquisition of CymaBay.BenzingaFDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal - Gilead SThe FDA granted accelerated approval for Gilead Sciences' LivDelzi (seladelpar) for primary biliary cholangitis (PBC), a rare autoimmune liver disease, based on Phase 3 trial data showing 62% of participants achieved biochemical response versus 20% on placebo. Gilead acquired seladelpar through its $4.3 billion purchase of CymaBay Therapeutics in February 2024, paying $32.50 per share in cash. The drug also remains under review by UK and European regulatory agencies.BenzingaGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And AssociatGilead Sciences announced positive interim results from the ASSURE study evaluating seladelpar in primary biliary cholangitis patients, with 70% of 148 patients achieving the composite response endpoint at 12 months and 37% experiencing ALP normalization. The drug, acquired from CymaBay Therapeutics in a deal valued at approximately $4 billion, demonstrated good tolerability with no treatment-related serious adverse events and rapid improvement in pruritus symptoms. The FDA has accepted the NDA for priority review with an anticipated decision in August 2024.BenzingaGilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment ProductGilead Sciences announced plans to quadruple its cell therapy cancer treatment production capacity to 10,000 annual patient treatments by 2026, up from 6,000 currently. The expansion reflects a strategic shift toward oncology beyond its core HIV business, with the company anticipating oncology products will constitute a third of its revenue by the decade's end. Gilead recently agreed to acquire CymaBay Therapeutics for $4.3 billion and, since acquiring Kite Pharma in 2017 for nearly $12 billion, has been expanding its CAR-T therapies Yescarta and Tecartus, which cost over $420,000 per treatment.